However, these researchers proposed that since not all PTCL cell lines or patient-derived samples are CD37+, screening for the expression of this antigen may be required in future preclinical and clinical investigations [88]. Here, CD37 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.